As of 3:59pm ET
| -0.35 / -1.67%|
The 13 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 28.00, with a high estimate of 32.00 and a low estimate of 4.00. The median estimate represents a +35.53% increase from the last price of 20.66.
The current consensus among 14 polled investment analysts is to Buy stock in Immunovant Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.